CLL Advocates Network

What CLL Advocates Network does

CLL Advocates Network (CLLAN) is a global patient advocacy organization dedicated to improving outcomes for people living with Chronic Lymphocytic Leukaemia (CLL). Founded in 2014 by patient advocates from Canada, the Czech Republic, France, Italy, Portugal, the UK, and the United States, CLLAN is formally hosted under the Leukemia Patient Advocates Foundation (LePAF), a patient-led non-profit foundation registered in Bern, Switzerland. The network serves 56 member organizations across 46 countries as of October 2025, acting as an international collective representative of CLL patient advocates. Its primary beneficiaries are national and regional non-profit CLL patient organizations, individual advocates, and CLL patients and carers seeking reliable information and peer support.

CLLAN does not operate proprietary technology products. Its core offerings consist of programmatic and digital resources: the annual CLL Horizons Conference for advocate capacity building, the Clinical Trials Hub, the Resource Hub, and the Advocacy Toolkit for developing local patient groups. The network also runs the CLL IC Taskforce (focused on immune-related challenges with clinician and advocate working groups), publishes patient-facing materials including the Karger-published 'Fast Facts for Patients' booklet and the 'Compromised' white paper (co-developed with AstraZeneca), conducts recurring global CLL Advocacy Surveys, and runs World CLL Day as an annual awareness campaign. Distribution occurs through the clladvocates.net website family, the quarterly 'CLL Matters' newsletter, webinars, social media, and the annual conference.

The organization operates as a non-profit funded entirely through grants and sponsorships from pharmaceutical companies with CLL-relevant franchises — including Takeda, AstraZeneca, AbbVie, Janssen, Lilly, BeiGene, MSD, and Loxo@Lilly. Membership for qualifying non-profit patient organizations is free. Governance rests with a 9-member Steering Committee (7 of whom are patients) chaired by Nick York, with Pierre Aumont as Vice Chair. CLLAN's GTM motion is community-led, scaling through membership recruitment, the biennial/annual CLL Horizons conference, webinars, and partnerships with clinical bodies including the European Hematology Association.

Name

CLL Advocates Network

Legal name

CLL Advocates Network (formally hosted by Leukemia Patient Advocates Foundation)

Website

https://clladvocates.net

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

CLL Advocates Network is a global non-profit patient advocacy network for Chronic Lymphocytic Leukaemia. Founded in 2014 and hosted by LePAF in Switzerland, it serves 56 member organizations across 46 countries via conferences, educational toolkits, surveys, and advocacy programs funded primarily by pharmaceutical grants.

Ownership category

akta.pro rank

Headquarters

HQ city

Bern

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Industry Grants and Sponsorship: CLLAN receives funding from pharmaceutical companies including Takeda, AstraZeneca, AbbVie, Janssen, Lilly, BeiGene, MSD, and Loxo through event grants, educational initiative support, and general sponsorship. This represents the primary funding mechanism for the non-profit organization.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

CLL Advocates Network (CLLAN) is a global patient advocacy network that coordinates and supports non-profit patient organizations dedicated to Chronic Lymphocytic Leukaemia (CLL). It provides member organizations with educational resources, advocacy tools, capacity-building conferences (CLL Horizons), digital platforms (Clinical Trials Hub, Resource Hub, Advocacy Toolkit), research surveys, and a coordinated international voice for improved CLL care and treatment access. Individual support to patients remains the scope of national or regional advocacy associations.

Product overview

The CLL Advocates Network (CLLAN) is a global patient advocacy network focused on improving Chronic Lymphocytic Leukaemia (CLL) patient outcomes. Rather than a unified software product, CLLAN offers a portfolio of programs and services including the annual CLL Horizons Conference for advocate capacity building, the CLL Clinical Trials Hub and Resource Hub for information access, the Advocacy Toolkit for patient group development, the CLL IC Taskforce addressing immune challenges, and the CLL Immune Challenges White Paper publication. Additional offerings include the World CLL Day awareness campaign, CLL Advocacy Survey research program, CLL Matters Newsletter, Digital Workshops/Webinars, a Membership Program for patient organizations, and educational resources such as the Fast Facts for Patients booklet, BTKi Patient Information Guide, and Good-Practice Guidelines. The organization is hosted under the Leukemia Patient Advocates Foundation (LePAF) umbrella.

Differentiator

Problem solved

Functional benefit

Products and services

• CLL Horizons Conference Annual international conference for CLL Patient Advocates featuring medical sessions, advocacy workshops, poster presentations, and networking opportunities, designed to build advocate capacity on medical and advocacy topics.
• CLL Clinical Trials Hub Online resource hub providing information about clinical trials for CLL patients, designed to help patients and advocates understand and access trial options.
• Resource Hub Global directory of CLL support provision and resources that maps support services available to CLL patients worldwide.
• Advocacy Toolkit Digital toolkit designed to empower advocates to support their local CLL communities with tools for building and developing patient advocacy groups.
• Membership Program Global membership network for CLL patient organizations offering Full, Associate, and Supporter membership tiers to build a strong CLL global community.
• World CLL Day Annual global awareness day dedicated to Chronic Lymphocytic Leukaemia, with annual advocacy themes such as 'Understand, Decide, Thrive.'
• CLL IC Taskforce Initiative bringing together patient advocates and clinicians to address immune-related challenges in CLL care, with working groups including the Advocate Working Group, Clinicians Working Group, and Operational Committee.
• Digital Workshops and Webinars Capacity-building workshops and webinars covering topics such as CLL treatment advances, patient group development, COVID-19 vaccination, and collaboration between patient groups and clinical groups.
• CLL Matters Newsletter Quarterly newsletter providing updates on upcoming events, projects, CLL-specific information, and member organization activities.
• CLL Advocacy Survey Global research survey program to explore CLL support provision, needs, available resources, and unmet needs worldwide, with 2021, 2023, and 2024 survey editions.
• CLL Immune Challenges White Paper White paper titled 'Compromised: Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia' addressing infection risks, autoimmune complications, and quality of life for CLL patients.
• Fast Facts for Patients – Chronic Lymphocytic Leukemia Patient information booklet co-authored with medical professionals (Kathryn Huntley, Professor Anna Schuh, Dr Alessandra Tedeschi) and published by Karger Publishing to empower individuals with CLL with knowledge about their condition and treatment options.
• BTKi Patient Information Guide Patient guide on Bruton tyrosine kinase inhibitors (BTKi) treatment for CLL.

Quantifiable outcome

• 56 member organizations from 46 countries
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered core.

• Leukemia & Lymphoma Society (LLS)coreStrategic or Co-development PartnerLLS is listed as a supporter and collaborative partner in CLLAN's mission to improve CLL patient outcomes through global advocacy.
• Leukemia Patient Advocates Foundation (LePAF)coreStrategic or Co-development PartnerLePAF is the umbrella organization hosting CLLAN. It is a patient-led non-profit foundation in Switzerland that acts as a legal platform for self-sustained patient advocacy initiatives and provides governance oversight.
• European Hematology Association (EHA)coreStrategic or Co-development PartnerCLLAN is one of 14 patient organizations actively collaborating with EHA. Patient advocates are represented in EHA committees and task forces, invited to speak at EHA events, and organize Patient Advocacy Sessions at EHA's Annual Congress.
• Acute Leukemia Advocates Network (ALAN)coreStrategic or Co-development PartnerCLLAN collaborates with ALAN on joint webinars covering topics like COVID-19 vaccination and immune challenges for leukemia patients.
• CML Advocates Network (CMLAN)coreStrategic or Co-development PartnerCLLAN collaborates with CMLAN on joint educational webinars addressing treatment advances across leukemia types.
• Leukaemia Care (UK)coreStrategic or Co-development PartnerLeukaemia Care collaborates with CLLAN on joint webinars covering CLL updates and treatment advances, and is a key partner in the UK CLL Forum.
• CLL IC TaskforcecoreStrategic or Co-development PartnerCLL IC Taskforce is a CLLAN initiative that brings together patient advocates and clinicians to address immune-related challenges in CLL care. The taskforce has working groups including Advocate Working Group, Clinicians Working Group, and Operational Committee.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Others

• European Hematology Association (EHA): Professional hematology society with which CLLAN collaborates directly (CLLAN is one of 14 patient organizations active with EHA, and advocates sit on EHA committees). Not a patient-advocacy peer itself, but the most important enabling clinical/regulatory counterpart for CLLAN's mission.

Emerging players

• CLL Ireland: National CLL patient organization in Ireland, founded by CLLAN Steering Committee member Michael Rynne. Smaller geographic scope than CLLAN but operates in the same niche with overlapping mission.
• International Myeloma Foundation (IMF): Global patient-driven myeloma organization with pharma sponsorship, member groups, and education programs. Comparable operating model focused on a different hematology cancer; smaller relative scope than LLS but broader than CLLAN-style niche networks. (Generally known peer)

Direct peers

• CLL Society: US-focused CLL-specific patient organization providing patient education, support, and access to expert care. Co-founded by CLLAN Steering Committee member Brian Koffman; shares the narrow CLL focus and pharma-supported operating model.
• Leukaemia Care: UK-based leukemia patient advocacy organization and named CLLAN partner on joint webinars and the UK CLL Forum. Operates in an adjacent leukemia niche with comparable advocacy, education, and support programs.
• Acute Leukemia Advocates Network (ALAN): Sister global advocacy network for acute leukemia, also hosted under LePAF and a named CLLAN collaborator. Operates the same membership/conference/resource-hub model focused on a different leukemia subtype.
• Lymphoma Coalition: Global network of lymphoma patient organizations, structurally analogous to CLLAN (membership network, global surveys, pharma sponsorship). Adjacent hematology indication with similar operational blueprint. (Generally known; corroborated by sister-network structure)
• Myeloma Patients Europe (MPE): European umbrella of myeloma patient organizations, operates the same multi-country membership-network model that CLLAN uses for CLL. Direct structural analog in a different hematology indication. (Generally known peer in the European patient-advocacy landscape)
• CML Advocates Network: Global patient advocacy network for chronic myeloid leukemia (CML), organized under the same LePAF umbrella as CLLAN. Structurally and operationally identical: member organizations, biennial Horizons-style conference, pharma sponsorship model, online resource hubs.

Broad incumbents

• Leukemia & Lymphoma Society (LLS): Large US blood-cancer nonprofit funding research and providing patient services across leukemia, lymphoma, myeloma, and other blood cancers. Listed as a CLLAN supporter; overlaps in CLL mission but at significantly larger scale and broader disease scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC5DMKIKEhnpBrT4zjkBMJ8Q
• Xtwitter.com/CLLAdvocates
• LinkedInlinkedin.com/company/clladvocates
• Facebookfacebook.com/CLLAdvocatesNetwork

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CLL Advocates Network